ISEND May Predict Clinical Outcomes for Advanced NSCLC Patients on PD-1/PD-L1 Inhibitors but Not Chemotherapies or Targeted Kinase Inhibitors

被引：0

作者：

Park, W. ^{[1
]}

Kwon, D. ^{[2
]}

Desai, A. ^{[1
]}

Florou, V. ^{[1
]}

Saravia, D. ^{[3
]}

Warsch, J. ^{[4
]}

Chae, Y. K. ^{[5
]}

Ishkanian, A. ^{[6
]}

Jahanzeb, M. ^{[7
]}

Mudad, R. ^{[8
]}

Lopes, G. ^{[9
]}

机构：

[1] Univ Miami, Sylvester Comprehens Canc Ctr, Hematol & Oncol, Miami, FL USA

[2] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med Biostat & Bioinformat, Miami, FL USA

[3] Univ Miami, Miller Sch Med, Internal Med, Miami, FL 33136 USA

[4] Univ Miami, Sylvester Comprehens Canc Ctr, Radiol, Miami, FL USA

[5] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL 60611 USA

[6] Univ Miami, Sylvester Comprehens Canc Ctr, Radiat Oncol, Miami, FL USA

[7] Univ Miami, Sylvester Comprehens Canc Ctr, Med Oncol, Miami, FL USA

[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Univ Miami, Sylvester Comprehens Canc Ctr, Global Oncol, Miami, FL USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

Predictive; PD-1; inhibitor; Clinical outcome;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.07-024

引用

页码：S2004 / S2004

页数：1

共 50 条

[1] PD-1/PD-L1 inhibitors
Sunshine, Joel
Taube, Janis M.
CURRENT OPINION IN PHARMACOLOGY, 2015, 23 : 32 - 38
[2] Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC
Bouhamama, Amine
Leporq, Benjamin
Faraz, Khuram
Foy, Jean-Philippe
Boussageon, Maxime
Perol, Maurice
Ortiz-Cuaran, Sandra
Ghiringhelli, Francois
Saintigny, Pierre
Beuf, Olivier
Pilleul, Frank
FRONTIERS IN RADIOLOGY, 2023, 3
[3] Trends in clinical development for PD-1/PD-L1 inhibitors
Yu, Jia Xin
Hodge, Jeffrey P.
Oliva, Cristina
Neftelinov, Svetoslav T.
Hubbard-Lucey, Vanessa M.
Tang, Jun
NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) : 163 - 164
[4] PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, Pedro Isaacsson
Antonarakis, Emmanuel S.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 475 - 486
[5] Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC
Jorgensen, Jan Trost
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2016, 16 (02) : 131 - 133
[6] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
Himuro, Hidetomo
Nakahara, Yoshiro
Igarashi, Yuka
Kouro, Taku
Higashijima, Naoko
Matsuo, Norikazu
Murakami, Shuji
Wei, Feifei
Horaguchi, Shun
Tsuji, Kayoko
Mano, Yasunobu
Saito, Haruhiro
Azuma, Koichi
Sasada, Tetsuro
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
[7] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
Hidetomo Himuro
Yoshiro Nakahara
Yuka Igarashi
Taku Kouro
Naoko Higashijima
Norikazu Matsuo
Shuji Murakami
Feifei Wei
Shun Horaguchi
Kayoko Tsuji
Yasunobu Mano
Haruhiro Saito
Koichi Azuma
Tetsuro Sasada
Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
[8] Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors
Wang, Miao
Zhen, Hongchao
Jiang, Xiaoyue
Lu, Yuting
Wei, Yuhan
Jin, Jiangtao
Li, Qin
IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1584 - 1595
[9] Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
Nakahara, Y.
Himuro, H.
Igarashi, Y.
Kouro, T.
Higashijima, N.
Matsuo, N.
Murakami, S.
Wei, F.
Horaguchi, S.
Tsuji, K.
Mano, Y.
Saito, H.
Azuma, K.
Naoki, K.
Sasada, T.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S614 - S614
[10] Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC
Rothschild, S. I.
Leger, P.
Castellanos, E. L.
Pillai, R. N.
York, S. J.
Horn, L.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →